Aimmune Therapeutics announced the launch of PACT-CP, a Patient-Centric Chronic Pancreatitis Registry study to better understand the unmet needs and therapeutic burden on patients with EPI due to chronic pancreatitis (CP). The study was designed using input from patients and expert advisors and will track approximately 400 patients at 20 gastroenterology sites across the United States. Data will be collected both during regular office visits and through mobile-friendly direct-to-patient surveys with the goal of better understanding: Unmet needs and therapeutic burden. Overall patient experience (symptoms, diet, quality of life and treatment satisfaction), Healthcare utilization outcomes in standard of care. Chronic pancreatitis is a chronic inflammatory and fibrotic disease of the pancreas with a prevalence of 42 to 73 per 100,000 adults in the United States.1 Up to 48% of patients with chronic pancreatitis develop EPI1, a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion.2 Impaired food digestion in patients with CP and EPI can result in nutrient malabsorption and malnutrition, as well as disturbed regulation of gastrointestinal (GI) motor and secretory functions.